New Developments in the Medical Management of Prostate Cancer
- 1 January 2010
- journal article
- review article
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 85 (1) , 77-86
- https://doi.org/10.4065/mcp.2009.0442
Abstract
No abstract availableFunding Information
- National Cancer Institute (CA091956)
This publication has 84 references indexed in Scilit:
- Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate CancerJournal of Clinical Oncology, 2009
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate CancerScience, 2009
- Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesisNature Genetics, 2009
- Mortality Results from a Randomized Prostate-Cancer Screening TrialNew England Journal of Medicine, 2009
- Screening and Prostate-Cancer Mortality in a Randomized European StudyNew England Journal of Medicine, 2009
- Radical Prostatectomy Versus Watchful Waiting in Localized Prostate Cancer: the Scandinavian Prostate Cancer Group-4 Randomized TrialJNCI Journal of the National Cancer Institute, 2008
- Cumulative effect of five genetic variants on prostate cancer risk in multiple study populationsThe Prostate, 2008
- RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acidThe Prostate, 2008
- Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate CancerJournal of Clinical Oncology, 2006
- Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate CancerScience, 2005